Sara Dauber joined the National Institute of Neurological Disorders and Stroke (NINDS) in 2020 as a Strategic Consultant to the NINDS Small Business Program. Sara brings 15 years of biopharmaceutical industry leadership experience. Prior to joining NINDS, Sara was the Senior Director of Corporate Development at Eccrine Systems Inc., a 60-person medical device startup. In this role, Sara brought in dilutive and non-dilutive capital to fund corporate activities including a $400K Economic Development Grant and a $5M letter of intent from the state of Ohio. She also supported Series B, bridge, and Series C fundraising efforts.
Prior to her work at Eccrine, Sara was Associate Director of Program and Alliance Management at FORUM Pharmaceuticals, a venture-backed company developing therapies for brain diseases. There she created and led cross-functional teams that drove the formulation and communication of clinical, regulatory, and commercial strategies for two Phase 1 therapeutics (in schizophrenia and Alzheimer’s disease). In prior roles Sara contributed to Biogen’s development of two Phase 3 therapeutics for hemophilia and negotiated in-licensing deals in business development at Alkermes.
Sara has an MBA from Harvard Business School and an undergraduate degree in Biological Sciences from Columbia University. As an equity analyst covering pharmaceutical stocks for a mutual fund company she earned a Chartered Financial Analyst charter.